The most common adverse effects are headache, which occurs in 4–11% of patients, and constipation in up to 6% of patients. In less than 1% of patients, other gastrointestinal disorders occur, as well as sleeplessness, first- and second-degree atrioventricular block, muscle pain and shortness of breath.<unk>  is similarly well tolerated as other 5-HT3 antagonists, and slightly less than placebo.
Palonosetron
Tropisetron
Alosetron
Granisetron
Cilansetron
Avacopan
Romidepsin
Tripelennamine